Discover the latest in clinical development, trials and clinical data management, from our in-house experts. Available on demand, now. Why not also explore our clinical white papers for even more information?
A Discussion on Regulatory and Operational Considerations This 1-hour webinar discusses how the COVID-19 pandemic has impacted clinical studies for rare diseases and how patient-centric trial design with regulatory consideration can be utilised to mitigate and manage potential delays and support patient recruitment in rare and orphan clinical trials. About…
Clinical trials for central nervous system (CNS) conditions have historically been notoriously difficult for a myriad of reasons with a failure rate…
Decentralisation has been one of the biggest outcomes of the COVID-19 pandemic. The speed and degree to which traditional healthcare…
Genomic sequencing techniques and bioinformatics have led us to a better understanding of cancer biology, resulting in a shift from…
In early clinical development, making changes to a study design after regulatory approval can cause significant delays. These can be avoided…
This 1-hour webinar reviews a published consensus statement from the British Journal of Cancer (BJC), looking at recommendations for effective…
In this webinar members of our specialist, early phase Project Management team discuss how they tackled the range of challenges…
Discussion topics include: Key challenges to improve cost-efficiency in clinical development of orphan drugs Regulatory evolution in the review process…
In this webinar the speakers discuss the use of integrated protocols (umbrella protocols) to maximise programme efficiency. Attendees will learn how…
If you are embarking on your clinical development plan, consider a non-invasive in vivo evaluation of drug delivery systems. Scintigraphy gives you the…
Successfully moving through to proof of concept and beyond This one-hour webinar focuses on conducting early phase Oncology studies. It…
Modular and adaptive clinical trials are rapidly expanding the ability of researchers to modify clinical trials based on emerging data, i.e. to…
Achieving Orphan Drug Designation is a significant step enabling your product to be licensed faster, in a cost-efficient manner, and achieve market exclusivity…